<DOC>
	<DOCNO>NCT01272323</DOCNO>
	<brief_summary>Cat allergy increasingly prevalent condition , affect 10-15 % patient allergic rhinoconjunctivitis and/or asthma . The purpose optional observational follow-on study evaluate rhinoconjunctivitis symptom exposure cat dander EEC among subject complete dose visit study CP005 approximately one year start treatment .</brief_summary>
	<brief_title>Cat-PAD Follow Study</brief_title>
	<detailed_description>Subjects complete dose visit post treatment challenge ( PTC ) study CP005 invite attend Screening Visit CP005A . Subjects attend 4 visit EEC successive day . Following last EEC visit follow-up visit perform 3-10 day later .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Inclusion Criteria Previously randomise study CP005 , complete treatment visit Post Treatment Challenge ( PTC ) . Exclusion Criteria `` Partly control '' `` uncontrolled '' asthma History anaphylaxis cat allergen FEV1 le 70 % predicted Subjects tolerate baseline challenge EEC Treatment betablockers , Alphaadrenoceptor blocker , Tranquillizers psychoactive drug A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>